| Literature DB >> 27751562 |
A Mekinian1, J Cohen2, G Kayem3, L Carbillon4, P Nicaise-Roland5, B Gaugler6, E Darai2, M Bornes2, O Fain7.
Abstract
About 1-3% of women experience early recurrent miscarriages, defined by ≥3 fetal loss before 14 weeks of gestation. About half of these recurrent early miscarriages could be related to a genetic cause. Pre-implantation genetic diagnosis is used in several European countries, but it is still prohibited in France except for couples at risk for transmission of severe genetic diseases. The immune dysregulation, and in particular allo-immune excessive response, could be responsible for fetal loss in remaining cases, although currently we lack biomarker to confirm the immune-mediated fetal loss. Several immunosuppressive and immunomodulatory treatments have been the subject of small studies in patients with early recurrent miscarriages. The available data do not allow to define the treatment recommendations in this topic, and further studies are necessary.Entities:
Keywords: Biological-targeted agents; Biothérapies; Fausses couches inexpliquées; Immunomodulation; Unexplained recurrent early miscarriages
Mesh:
Substances:
Year: 2016 PMID: 27751562 DOI: 10.1016/j.revmed.2016.08.001
Source DB: PubMed Journal: Rev Med Interne ISSN: 0248-8663 Impact factor: 0.728